HTG Molecular Diagnostics (HTGM) Reports Q4 Loss Per Share of $0.83
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Partners Cuts Price Target on HTG Molecular Diagnostics (HTGM) Following 4Q
March 28, 2016 9:56 AM EDTLeerink Partners maintained an Outperform rating on HTG Molecular Diagnostics (NASDAQ: HTGM), and cut the price target to $5.00 (from $10.00), following the company's 4Q. As anticipated, HTGM launched its research-use lung fusion panel in 4Q and completed submission for premarket approval with the FDA... More
